Stock Track | Adaptive Biotechnologies Soars 5.23% Pre-market on Strong Q3 Results and Analyst Upgrades

Stock Track11-06

Adaptive Biotechnologies Corp (NASDAQ: ADPT) shares surged 5.23% in pre-market trading on Thursday, following the company's impressive third-quarter financial results and a series of analyst upgrades.

The biotechnology firm reported quarterly adjusted earnings of 6 cents per share, significantly beating the analyst consensus estimate of a 15-cent loss. This marks a substantial improvement from the 22-cent loss reported in the same quarter last year. Revenue also exceeded expectations, reaching $93.97 million, a 102.4% increase year-over-year and well above the anticipated $64.64 million.

In response to the strong performance, several Wall Street analysts raised their price targets for Adaptive Biotechnologies. JP Morgan increased its target from $17 to $20, while TD Cowen boosted its projection from $18 to $22. The positive sentiment is reflected in the current average analyst rating of "buy," with 7 out of 8 analysts recommending either "strong buy" or "buy." The median 12-month price target now stands at $17.00, slightly above the last closing price of $16.92. This wave of optimism has contributed to the stock's impressive 182.2% gain year-to-date, underlining investor confidence in the company's growth trajectory and market potential in the biotechnology sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1145369608?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 17:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145369608","market":"us","top_or_hot":-1,"title":"Stock Track | Adaptive Biotechnologies Soars 5.23% Pre-market on Strong Q3 Results and Analyst Upgrades","media":"Stock Track","content":"<p>Adaptive Biotechnologies Corp (NASDAQ: ADPT) shares surged 5.23% in pre-market trading on Thursday, following the company's impressive third-quarter financial results and a series of analyst upgrades.</p>\n\n<p>The biotechnology firm reported quarterly adjusted earnings of 6 cents per share, significantly beating the analyst consensus estimate of a 15-cent loss. This marks a substantial improvement from the 22-cent loss reported in the same quarter last year. Revenue also exceeded expectations, reaching $93.97 million, a 102.4% increase year-over-year and well above the anticipated $64.64 million.</p>\n\n<p>In response to the strong performance, several Wall Street analysts raised their price targets for Adaptive Biotechnologies. JP Morgan increased its target from $17 to $20, while TD Cowen boosted its projection from $18 to $22. The positive sentiment is reflected in the current average analyst rating of \"buy,\" with 7 out of 8 analysts recommending either \"strong buy\" or \"buy.\" The median 12-month price target now stands at $17.00, slightly above the last closing price of $16.92. This wave of optimism has contributed to the stock's impressive 182.2% gain year-to-date, underlining investor confidence in the company's growth trajectory and market potential in the biotechnology sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Adaptive Biotechnologies Soars 5.23% Pre-market on Strong Q3 Results and Analyst Upgrades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Adaptive Biotechnologies Soars 5.23% Pre-market on Strong Q3 Results and Analyst Upgrades\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-06 17:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Adaptive Biotechnologies Corp (NASDAQ: ADPT) shares surged 5.23% in pre-market trading on Thursday, following the company's impressive third-quarter financial results and a series of analyst upgrades.</p>\n\n<p>The biotechnology firm reported quarterly adjusted earnings of 6 cents per share, significantly beating the analyst consensus estimate of a 15-cent loss. This marks a substantial improvement from the 22-cent loss reported in the same quarter last year. Revenue also exceeded expectations, reaching $93.97 million, a 102.4% increase year-over-year and well above the anticipated $64.64 million.</p>\n\n<p>In response to the strong performance, several Wall Street analysts raised their price targets for Adaptive Biotechnologies. JP Morgan increased its target from $17 to $20, while TD Cowen boosted its projection from $18 to $22. The positive sentiment is reflected in the current average analyst rating of \"buy,\" with 7 out of 8 analysts recommending either \"strong buy\" or \"buy.\" The median 12-month price target now stands at $17.00, slightly above the last closing price of $16.92. This wave of optimism has contributed to the stock's impressive 182.2% gain year-to-date, underlining investor confidence in the company's growth trajectory and market potential in the biotechnology sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADPT","symbol_name":"Adaptive Biotechnologies Corp","start_time":0,"source_url":"","article_id":"1145369608","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145369608","pubTimestamp":1762422640,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Adaptive Biotechnologies Corp (NASDAQ: ADPT) shares surged 5.23% in pre-market trading on Thursday, following the company's impressive third-quarter financial results and a series of analyst...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADPT":"Adaptive Biotechnologies Corp"},"translate_title":"个股追踪|Adaptive Biotechnologies盘前飙升5.23%，因第三季度业绩强劲和分析师上调评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADPT":1},"content_text":"Adaptive Biotechnologies Corp (NASDAQ: ADPT) shares surged 5.23% in pre-market trading on Thursday, following the company's impressive third-quarter financial results and a series of analyst upgrades.\nThe biotechnology firm reported quarterly adjusted earnings of 6 cents per share, significantly beating the analyst consensus estimate of a 15-cent loss. This marks a substantial improvement from the 22-cent loss reported in the same quarter last year. Revenue also exceeded expectations, reaching $93.97 million, a 102.4% increase year-over-year and well above the anticipated $64.64 million.\nIn response to the strong performance, several Wall Street analysts raised their price targets for Adaptive Biotechnologies. JP Morgan increased its target from $17 to $20, while TD Cowen boosted its projection from $18 to $22. The positive sentiment is reflected in the current average analyst rating of \"buy,\" with 7 out of 8 analysts recommending either \"strong buy\" or \"buy.\" The median 12-month price target now stands at $17.00, slightly above the last closing price of $16.92. This wave of optimism has contributed to the stock's impressive 182.2% gain year-to-date, underlining investor confidence in the company's growth trajectory and market potential in the biotechnology sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1145369608","isCrawlerRequest":true}